Shanmuga Sozhamannan, PhD, Technical Coordinator, Joint Project Lead, Defense Biological Product Assurance Office (DBPAO), CBRND Enabling Biotechnologies (JPL CBRND EB)
Diagnostic assays are crucial tools to test, diagnose and treat infectious and other diseases. They continue to remain extremely valuable in the current COVID-19 pandemics not only to provide appropriate health care for infected and symptomatic individuals as needed but also for implementing public health measures such as test, trace and isolate infected and asymptomatic individuals to prevent further transmission of the virus. Sustained transmission and unhindered proliferation of the pathogen across the population during a continuous, ongoing pandemic such as COVID-19, has resulted in many variants with mutations. These mutations may lead to signature erosion, a phenomenon wherein diagnostic tests developed using the genetic sequence of the original pathogen may fail and cause false-negative results in a sample containing a new variant. We have developed a tool called PSET (PCR Signature Erosion Tool) to monitor the performance of diagnostic tests in silico using the genome sequences of pathogens. We will present and discuss our data on Ebola, Lassa, and SARS-CoV-2 in demonstrating the power of real-time in silico monitoring on identifying diagnostics failures, thereby driving rapid modification of assays if signature erosion is evident.